Integra Holdings focuses on biopharmaceutical companies with products in clinical and pre-clinical stages of development, which present innovation and competitive advantages in their respective industries. Integra Holdings’ portfolio is composed of companies operating in the fields of cancer therapy, Alzheimer’s disease, infectious diseases, inflammation and bipolar disorder.
Owned by Yissum, the technology transfer company of the Hebrew University of Jerusalem, Integra holdings offers an attractive combination of a robust portfolio, an existing extensive marketing network enhanced by Yissum and an on-going deal-flow, originating from the Hebrew University and Sha’arei Zedek Medical Center.
Integra Holdings’ robust portfolio is currently composed of companies operating in diverse therapeutic fields of high industry interest ranging from oncology to Alzheimer’s disease, and from infectious diseases to allergies, and includes four Phase II companies, three Phase I ready companies and one company in pre-clinical stages of development. The companies are Atox Bio, Avraham Pharmaceuticals, Ayana, Hill Applied Medical, LipoCure, Lipomedix and Tiltan Pharma.
Integra Holdings announced in October 2012 the closing of a U.S. $7.0 million first round of financing at a pre-money value of U.S. $25 million. It is seeking further investment.
Address: Hi-Tech Park, Edmond J. Safra Campus, Givat-Ram, Jerusalem, Israel
Name: Liana Patt, PhD, MBA